|
|
|
| The Stability Analysis of IL3 Fusion Protein and Contrast Study of Its Biologic Activity Before and After Protein Modification |
| ZHANG Yan-jun1, LIU Rong2, ZHANG Meng-nan1, ZHANG Xiao-long3, YUANXiang-fei3, MIAO Qing-fang1, ZHEN Yong-su1 |
1. State Key Laboratory of Experimental Hematology, Institute of Hematology&Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China;
2. Henan Province Academician Workstation, the People’s Hospital of Zhengzhou, Henan 450053, China;
3. Institute of Medicimal Biotechnology Academy of Medical Sciences&Peking Union Medical College, Beijing 100050, China |
|
|
|
Abstract The interleukin-3 receptor alpha chain (IL-3Ra or CD123) was strongly expressed in AML stem cells but it was not detectable in hemopoietic stem cell, which can be used as target for treatment.We constructed IL3-LDP expression plasmid to produce fusion protein for tumor stem cells targeted removing.We found that the residues at 131 and 132 in IL-3 is the strategic positions leading to protein-degradation by protein mass spectrometry.The stability of IL3 fusion protein can be significantly improved after transformed mainly aiming at these two positions by genetic modification , moreover, the yield and binding activity were not changed. This conclusion may be widely applied to improving protein stability.
|
|
Received: 28 October 2012
Published: 25 March 2013
|
|
|
|
|
[1] Blair A,Sutherland H J. Primitive acute myeloid leukemia cells with long term proliferative ability in vitro and in vivo lack surface expression of c-kit(CD117). Exp Hematol,2000,28:660-671.
[2] Jordan C T,Upchurch D,Szilvassy S J,et al. The interleukin-3 receptor alpha chain in a unique marker for human acute myelogenous leukemia stem cells. Leukemia,2000,14:1777-1784.
[3] Hu J L, Xue Y C, Xie M Y, et al. A new macromolecular antitumor antibiotic, C-1027. I. Discovery, taxonomy of producing organism, fermentation and biological activity. J Antibiot (Tokyo) 1988,41(11): 1575-1579.
[4] 任思楣,张砚君,彭洪薇,等.靶向白血病干细胞CD123的毒性融合蛋白的制备.白血病.淋巴瘤,2011,20(8):490-493. Ren S M, Zhang Y J,Peng H W, et al. Preparation of a toxicity fusion protein targeting to CD123 on leukemia stem cell.Journal of Leukemia & Lymphoma,2011, 20(8):490-493.
[5] Frankel A E, McCubrey J A, Miller M S, et al. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias. Leukemia, 2000,14:576–585.
[6] Michaela F B, Arthur E F, Richard L A. A diphtheria Toxin-Interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Cancer Research, 2002,15:1730-1736.
[7] Liu T F, Urieto J O, Moore J E, et al. Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity. Exp Hematol, 2004,32:277-281.
[8] Hogge D E, Yalcintepe L, Wong S H, et al. Variant diphtheria toxin interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors. Cancer Therapy: Preclinical, 2006,12(4):1284-1291.
[9] Cohen K A, Liu T F, Cline J M, et al.Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey. Cancer Immunol Immunother, 2005,54(8):799-806.
[10] Zhen Y S,Ming X Y,Yu B,et al.A new macromolecular antitumor antibiotic,C-1027 Ⅲ Antitumor activity.J Antibiot(tokyo) ,1989,42(8):1294-1298.
[11] 高瑞娟,李电东,甄永苏. 烯二炔类抗肿瘤抗生素力达霉素的作用机制研究进展.中国新药杂志, 2006,15(13):1039-1043. Gao R J, Li D D, Zhen Y S. Study on mechanisms of action of enediyne antitumor antibiotic lidamycin.Chinese Journal of New Drugs, 2006,15(13):1039-1043. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
